Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Zafgen Inc    ZFGN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
3.68(c) 3.57(c) 3.95(c) 3.8(c) 3.71(c) Last
154 965 187 424 296 495 240 111 2 226 695 Volume
+1.10% -2.99% +10.64% -3.80% -2.37% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -63,6 M
Net income 2017 -63,2 M
Finance 2017 70,8 M
Yield 2017 -
Sales 2018 -
EBIT 2018 -65,7 M
Net income 2018 -65,4 M
Finance 2018 112 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 0
EV / Sales2018 0
Capitalization 102 M
More Financials
Company
Zafgen, Inc. is a biopharmaceutical company, which engages in the development of anti-obesity therapeutics that restores normal fat metabolism and regulatory pathways.Its product: Beloranib, which is under phase 2 clinical development as a treatment for obesity and hyperphagia in Prader-Willi... 
More about the company
Surperformance© ratings of Zafgen Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on ZAFGEN INC
06/23 ZAFGEN, INC. (NASDAQ : ZFGN) Files An 8-K Submission of Matters to a Vote of Sec..
06/23 ZAFGEN, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
06/13 Zafgen to Present at the JMP Securities Life Sciences Conference
06/12 ZAFGEN : Presents New Data Highlighting Potential of ZGN-1061 for the Treatment ..
06/10 ZAFGEN : Presents New Data Highlighting Potential of ZGN-1061 for the Treatment ..
06/10 Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment..
06/06 ZAFGEN : to Present Two Late-Breaking Abstracts for ZGN-1061 at the American Dia..
06/06 Zafgen to Present Two Late-Breaking Abstracts for ZGN-1061 at the American Di..
05/20 ZAFGEN : U.S. Patents Awarded to Inventors in Tennessee (May 20)
05/10 ZAFGEN : reports 1Q loss
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/21Zafgen $ZFGN Receiving Somewhat Positive News Coverage, Study Shows  
06/16Zafgen $ZFGN Given Media Sentiment Rating of -0.06  
06/14Zafgen to Present at the JMP Securities Life Sciences Conference  
06/13Zafgen to Present at the JMP Securities Life Sciences Conference  
06/13Zafgen $ZFGN Receiving Somewhat Positive Press Coverage, Analysis Shows  
More tweets
Qtime:15
News from SeekingAlpha
05/10 Zafgen's Second Act
05/09 Zafgen misses by $0.05
05/05 Zafgen Gets One Last Fat Chance
05/05 PREMARKET GAINERS AS OF 9 : 05 am
05/05 Zafgen updates on obesity drug
Advertisement
Chart ZAFGEN INC
Duration : Period :
Zafgen Inc Technical Analysis Chart | ZFGN | US98885E1038 | 4-Traders
Full-screen chart
Technical analysis trends ZAFGEN INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 6,50 $
Spread / Average Target 75%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Thomas E. Hughes President, Chief Executive Officer & Director
Peter Barrett Chairman
Patricia L. Allen CFO, Treasurer & Principal Accounting Officer
Dennis D. Kim Chief Medical Officer
Bruce Lee Booth Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ZAFGEN INC19.50%102
AMGEN17.98%126 856
CELGENE CORPORATION16.03%104 873
GILEAD SCIENCES-1.52%92 150
REGENERON PHARMACEUTIC..43.43%54 987
VERTEX PHARMACEUTICALS83.97%33 251
More Results